GHR exon 3 polymorphism: Association with type 2 diabetes mellitus and metabolic disorder

Growth Hormone and IGF Research

Volumn 17, Issue 5, 2007, Pages 392-398

  Strawbridge, R J ^a   Karvestedt L ^a   Li, C ^a   Efendic, S ^a   Ostenson C G ^a   Gu, H F ^a   Brismar, K ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

BMI; CRP; Exon 3 variants; Growth hormone receptor; IGF I; Type 2 diabetes mellitus

Indexed keywords

C PEPTIDE; C REACTIVE PROTEIN; GENOMIC DNA; GROWTH HORMONE RECEPTOR; LIPID; SOMATOMEDIN C;

ADULT; ALLELE; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE DURATION; DNA EXTRACTION; DNA SEQUENCE; EXON; FEMALE; GEL ELECTROPHORESIS; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GLUCOSE TOLERANCE; HOMOZYGOSITY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION;

ADULT; AGED; BLOOD GLUCOSE; CARRIER PROTEINS; DIABETES MELLITUS, TYPE 2; EXONS; FEMALE; GLUCOSE INTOLERANCE; HUMANS; INSULIN; MALE; METABOLIC DISEASES; MIDDLE AGED; POLYMORPHISM, GENETIC; PROINSULIN; REFERENCE VALUES;

EID: 34548279858     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2007.04.005     Document Type: Article

References (24)

1. Dominici F.P., Argentino D.P., Munoz M.C., Miquet J.G., Sotelo A.I., and Turyn D. Influence of the crosstalk between growth hormone and insulin signaling on the modulation of insulin sensitivity. Growth Horm. IGF Res. 15 (2005) 324-336
2. Urbanek M., Russell J.E., Cooke N.E., and Liebhaber S.A. Functional characterization of the alternatively spliced, placental human growth hormone receptor. J. Biol. Chem. 268 (1993) 19025-19032
3. Pantel J., Grulich-Henn J., Bettendorf M., Strasburger C.J., Heinrich U., and Amselem S. Heterozygous nonsense mutation in exon 3 of the growth hormone receptor (GHR) in severe GH insensitivity (Laron syndrome) and the issue of the origin and function of the GHRd3 isoform. J. Clin. Endocrinol. Metab. 88 (2003) 1705-1710
4. Kratzsch J., Wu Z., Kiess W., Dehmel B., Bosse-Henck A., Reuter W., Pflaum C.D., and Strasburger C.J. The exon 3-retaining and the exon 3-deleted forms of the growth hormone-binding protein (GHBP) in human serum are regulated differently. Clin. Endocrinol. (Oxf.) 54 (2001) 61-68
5. Dos Santos C., Essioux L., Teinturier C., Tauber M., Goffin V., and Bougneres P. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat. Genet. 36 (2004) 720-724
6. Vaessen N., Heutink P., Janssen J.A., Witteman J.C., Testers L., Hofman A., Lamberts S.W., Oostra B.A., Pols H.A., and van Duijn C.M. A polymorphism in the gene for IGF-I: functional properties and risk for type 2 diabetes and myocardial infarction. Diabetes 50 (2001) 637-642
7. Frystyk J., Ledet T., Moller N., Flyvbjerg A., and Orskov H. Cardiovascular disease and insulin-like growth factor I. Circulation 106 (2002) 893-895
8. Wallander M., Brismar K., Ohrvik J., Ryden L., and Norhammar A. Insulin-like growth factor I: a predictor of long-term glucose abnormalities in patients with acute myocardial infarction. Diabetologia 49 (2006) 2247-2255
9. Hilding A., Brismar K., Degerblad M., Thoren M., and Hall K. Altered relation between circulating levels of insulin-like growth factor-binding protein-1 and insulin in growth hormone-deficient patients and insulin-dependent diabetic patients compared to that in healthy subjects. J. Clin. Endocrinol. Metab. 80 (1995) 2646-2652
10. McKay J.D., Kaaks R., Johansson M., Biessy C., Wiklund F., Balter K., Adami H.O., Boillot C., Gioia-Patricola L., Canzian F., Stattin P., and Gronberg H. Haplotype-based analysis of common variation in the growth hormone receptor gene and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 16 (2007) 169-173
11. Blum W.F., Machinis K., Shavrikova E.P., Keller A., Stobbe H., Pfaeffle R.W., and Amselem S. The growth response to growth hormone (GH) treatment in children with isolated GH deficiency is independent of the presence of the exon 3-minus isoform of the GH receptor. J. Clin. Endocrinol. Metab. (2006)
12. Binder G., Baur F., Schweizer R., and Ranke M.B. The d3-growth hormone (GH) receptor polymorphism is associated with increased responsiveness to GH in Turner syndrome and short small-for-gestational-age children. J. Clin. Endocrinol. Metab. 91 (2006) 659-664
13. Jorge A.A., Marchisotti F.G., Montenegro L.R., Carvalho L.R., Mendonca B.B., and Arnhold I.J. Growth hormone (GH) pharmacogenetics: influence of GH receptor exon 3 retention or deletion on first-year growth response and final height in patients with severe GH deficiency. J. Clin. Endocrinol. Metab. 91 (2006) 1076-1080
14. Pantel J., Machinis K., Sobrier M.L., Duquesnoy P., Goossens M., and Amselem S. Species-specific alternative splice mimicry at the growth hormone receptor locus revealed by the lineage of retroelements during primate evolution. J. Biol. Chem. 275 (2000) 18664-18669
15. Pilotta A., Mella P., Filisetti M., Felappi B., Prandi E., Parrinello G., Notarangelo L.D., and Buzi F. Common polymorphisms of the growth hormone (GH) receptor do not correlate with the growth response to exogenous recombinant human GH in GH-deficient children. J. Clin. Endocrinol. Metab. 91 (2006) 1178-1180
16. Carrascosa A., Esteban C., Espadero R., Fernandez-Cancio M., Andaluz P., Clemente M., Audi L., Wollmann H., Fryklund L., and Parodi L. The d3-Growth Hormone Receptor Polymorphism does not influence the effect of GH treatment (66 μg/K/day) or the spontaneous growth in short non-GH-deficient small for gestational-age children: results from a two-year controlled prospective study in 170 Spanish patients. J. Clin. Endocrinol. Metab. (2006)
17. Audi L., Esteban C., Carrascosa A., Espadero R., Perez-Arroyo A., Arjona R., Clemente M., Wollmann H., Fryklund L., and Parodi L.A. Exon 3-deleted/full-length growth hormone receptor polymorphism (d3/fl-GHR) genotype frequencies in Spanish short small-for-gestational-age (SGA) children and adolescents (n = 247) and in an adult control population (n = 289) show increased fl/fl in short SGA. J. Clin. Endocrinol. Metab. (2006)
18. Koenig W., Sund M., Frohlich M., Fischer H.G., Lowel H., Doring A., Hutchinson W.L., and Pepys M.B. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99 (1999) 237-242
19. Siemes C., Visser L.E., Coebergh J.W., Splinter T.A., Witteman J.C., Uitterlinden A.G., Hofman A., Pols H.A., and Stricker B.H. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J. Clin. Oncol. 24 (2006) 5216-5222
20. Levy-Lahad E., and Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br. J. Cancer 96 (2007) 11-15
21. Lindmark F., Jonsson B.A., Bergh A., Stattin P., Zheng S.L., Meyers D.A., Xu J., and Gronberg H. Analysis of the macrophage scavenger receptor 1 gene in Swedish hereditary and sporadic prostate cancer. Prostate 59 (2004) 132-140
22. Meneilly G.S., and Tessier D. Diabetes in elderly adults. J. Gerontol. A Biol. Sci. Med. Sci. 56 (2001) M5-M13
23. Hujeirat Y., Hess O., Shalev S., and Tenenbaum-Rakover Y. Growth hormone receptor sequence changes do not play a role in determining height in children with idiopathic short stature. Horm. Res. 65 (2006) 210-216
24. Horan M., Newsway V., Yasmin, Lewis M.D., Easter T.E., Rees D.A., Mahto A., Millar D.S., Procter A.M., Scanlon M.F., Wilkinson I.B., Hall I.P., Wheatley A., Blakey J., Bath P.M., Cockcroft J.R., Krawczak M., and Cooper D.N. Genetic variation at the growth hormone (GH1) and growth hormone receptor (GHR) loci as a risk factor for hypertension and stroke. Hum. Genet. (2006)